Torsades de Pointes associated with intravenous haloperidol in critically ill patients.
In this retrospective case-control study, 8 of 223 consecutive patients (3.6%) treated with intravenous haloperidol developed torsades de pointes, and were compared with 41 patients randomly selected as controls. The likelihood of torsades de pointes associated with intravenous haloperidol is significantly greater in patients receiving > or = 35 mg over 24 hours or in those with a QTc interval of >500 ms, or both.
Sharma
N D
ND
Department of Internal Medicine, Henry Ford Hospital, and the College of Pharmacy, Wayne State University, Detroit, Michigan 48202, USA.
Rosman
H S
HS
Padhi
I D
ID
Tisdale
J E
JE
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D016638:Critical Illness; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016171:Torsades de Pointes / Q000139:chemically induced*
D018492:Dopamine Antagonists; D006220:Haloperidol